BRPI0714211B8 - derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende - Google Patents

derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende

Info

Publication number
BRPI0714211B8
BRPI0714211B8 BRPI0714211A BRPI0714211A BRPI0714211B8 BR PI0714211 B8 BRPI0714211 B8 BR PI0714211B8 BR PI0714211 A BRPI0714211 A BR PI0714211A BR PI0714211 A BRPI0714211 A BR PI0714211A BR PI0714211 B8 BRPI0714211 B8 BR PI0714211B8
Authority
BR
Brazil
Prior art keywords
4alkyl
4alkyloxy
5alkyl
hydroxy
represents hydrogen
Prior art date
Application number
BRPI0714211A
Other languages
English (en)
Inventor
Papanikos Alexandra
Jean Edgard Freyne Eddy
Anne Mevellec Laurence
Willems Marc
Henri Storck Pierre
Ten Holte Peter
Constant Johan Embrechts Werner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0714211A2 publication Critical patent/BRPI0714211A2/pt
Publication of BRPI0714211B1 publication Critical patent/BRPI0714211B1/pt
Publication of BRPI0714211B8 publication Critical patent/BRPI0714211B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/54—Silicon-containing compounds
    • C08K5/544—Silicon-containing compounds containing nitrogen

Abstract

derivados de mtki quinazolina. a presente invenção refere-se aos compostos da fórmula às formas de n-óxido, aos sais de adição farmaceuticamente aceitáveis e às formas estereoquimicamente isoméricas destes, em que y representa -c3-9alquil-, -c1-5alquil-nr6-c1-5alquil- ou -c1-5alquil-nr7-co-c1-5alquil-; x1 representa -o-; x2 representa nr5-c1-2alquil-; r1 representa hidrogênio, halo ou het3-o-; r2 representa hidrogênio; r3 representa hidróxi, c1-4alquilóxi- ou c1-4alquilóxi substituído com um ou dois substituintes, cada um independentemente, selecionados de het4, hidróxi, c1-4 alquilóxi-, c1-4alquilóxi-c1-4alquilóxi e nr9r10; r5 representa hidrogênio ou c1-4alquila; r6 representa hidrogênio ou c1-4alquila; r7 representa hidrogênio; r9 e r10, cada um independentemente, representam hidrogênio; c1-4alquil-s(=o)-; c1-4alquila ou c1-4alquila substituída com hidróxi; het3 representa piridinila opcionalmente substituída com c1-4alquila; het4 representa morfolinila, piperidinila ou piperazinila em que o referido het4 é opcionalemente substituída com hidróxi-c1-4alquila ou c1-4alquil-s(=o)2-c1-4alquil-.
BRPI0714211A 2006-07-13 2007-07-12 derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende BRPI0714211B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06117185 2006-07-13
EP06117185.6 2006-07-13
PCT/EP2007/057200 WO2008006884A2 (en) 2006-07-13 2007-07-12 Mtki quinazoline derivatives

Publications (3)

Publication Number Publication Date
BRPI0714211A2 BRPI0714211A2 (pt) 2013-01-01
BRPI0714211B1 BRPI0714211B1 (pt) 2020-11-17
BRPI0714211B8 true BRPI0714211B8 (pt) 2021-05-25

Family

ID=37814194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714211A BRPI0714211B8 (pt) 2006-07-13 2007-07-12 derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende

Country Status (13)

Country Link
US (1) US8492377B2 (pt)
EP (1) EP2044084B1 (pt)
JP (2) JP2009542778A (pt)
CN (1) CN101490060B (pt)
AU (1) AU2007274284B2 (pt)
BR (1) BRPI0714211B8 (pt)
CA (1) CA2654583C (pt)
DK (1) DK2044084T3 (pt)
EA (1) EA014779B1 (pt)
ES (1) ES2569428T3 (pt)
HK (1) HK1132994A1 (pt)
MX (1) MX2009000456A (pt)
WO (1) WO2008006884A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4936897B2 (ja) * 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
US10688093B2 (en) 2015-09-09 2020-06-23 Lau Warren C Methods, compositions, and uses of novel Fyn kinase inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (pt) 1956-06-11
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
NZ181256A (en) 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4126688A (en) 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives
US4442278A (en) 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
EE200000386A (et) 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
ATE316527T1 (de) 1999-08-27 2006-02-15 Boehringer Ingelheim Pharma Substituierte indolinone als tyrosinkinase inhibitoren
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
PL202812B1 (pl) * 2000-08-21 2009-07-31 Astrazeneca Ab Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
MXPA04008356A (es) 2002-02-28 2005-09-12 Univ Temple (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas con un grupo amino y en la posicion 4 para tratar trastornos poliferativos.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
BR0308902A (pt) 2002-03-30 2005-01-04 Boehringer Ingelheim Pharma 4-(n-fenilamino)-quinazolinas/quinolinas como inibidoras da tirosina cinase
US7504408B2 (en) 2002-07-09 2009-03-17 Astrazeneca Ab Quinzoline derivatives for use in the treatment of cancer
ES2392426T3 (es) 2002-07-18 2012-12-10 Janssen Pharmaceutica Nv Inhibidores de quinasas con triazina sustituida
JP2006505522A (ja) 2002-08-08 2006-02-16 スミスクライン ビーチャム コーポレーション チオフェン化合物
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JP4936897B2 (ja) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
EA200601176A1 (ru) 2003-12-18 2006-10-27 Янссен Фармацевтика Н.В. 3-цианохинолиновые производные с антипролиферативной активностью
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JP5345388B2 (ja) 2005-06-30 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 環式アニリノ−ピリジノトリアジン
KR20080090390A (ko) 2005-11-16 2008-10-08 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
JP2007135441A (ja) 2005-11-16 2007-06-07 Kenichi Mikiya 新規タンパク質及びそれをコードする遺伝子
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
MX2009004436A (es) 2006-10-27 2009-05-22 Janssen Pharmaceutica Nv Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3.
US20080219975A1 (en) 2006-10-27 2008-09-11 Timothy Pietro Suren Perera Vegfr3 inhibitors
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2009112439A1 (en) 2008-03-10 2009-09-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors

Also Published As

Publication number Publication date
CN101490060B (zh) 2012-04-11
JP5744127B2 (ja) 2015-07-01
WO2008006884A2 (en) 2008-01-17
EP2044084B1 (en) 2016-02-17
EA200970121A1 (ru) 2009-06-30
EP2044084A2 (en) 2009-04-08
MX2009000456A (es) 2009-01-27
JP2013249307A (ja) 2013-12-12
EA014779B1 (ru) 2011-02-28
CN101490060A (zh) 2009-07-22
US20100029627A1 (en) 2010-02-04
AU2007274284A1 (en) 2008-01-17
CA2654583A1 (en) 2008-01-17
BRPI0714211A2 (pt) 2013-01-01
WO2008006884A3 (en) 2008-03-06
ES2569428T3 (es) 2016-05-10
US8492377B2 (en) 2013-07-23
AU2007274284B2 (en) 2012-04-26
BRPI0714211B1 (pt) 2020-11-17
CA2654583C (en) 2015-11-24
DK2044084T3 (en) 2016-05-09
HK1132994A1 (en) 2010-03-12
JP2009542778A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
BRPI0714211B8 (pt) derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende
BR112018071216A2 (pt) inibidores de bromodomínios
BR112021026395A2 (pt) Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
CR20120302A (es) Derivados bencimidazol-imidazol
BRPI0612888B8 (pt) anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica
BRPI0507065A (pt) derivados de quinolina e seu uso como inibidores micobacterianos
BR112015025052A2 (pt) derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
BR112015022551A2 (pt) inibidores de amido pirrol
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
BR112015020242A2 (pt) sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BR112015028461A2 (pt) derivados de sulfamoílpirrolamida e o seu uso como medicamentos para o tratamento da hepatite b
TW200745040A (en) Quinoline derivatives
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
BR112014001801A2 (pt) indazóis
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
UY30811A1 (es) Derivados de amina, composiciones conteniéndolos, procesos de preparacion, compuestos intermedios y aplicaciones
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF